VOLUME 10 (2019)
View Archive »
About The Cover
The cover for issue 2 of Oncotarget features Supplementary Figure 4, "Using principal component analysis, distributions of subtypes in the Burstein et al. training set and our data set are shown," by Ding, et al.
|
|
Table of Contents
Editorial
|
| The extended 4year followup results of the ELOQUENT2 trial |
|
https://doi.org/10.18632/oncotarget.26527
|
| 82-83 |
|
| We shall overcome drug resistance some day |
|
https://doi.org/10.18632/oncotarget.26550
|
| 84-85 |
Research Papers
|
| Association between thyroid function and diabetic nephropathy in euthyroid subjects with type 2 diabetes mellitus: a crosssectional study in China |
|
https://doi.org/10.18632/oncotarget.26265
|
| 88-97 |
|
| Chemerin acts via CMKLR1 and GPR1 to stimulate migration and invasion of gastric cancer cells: putative role of decreased TIMP1 and TIMP2 |
|
https://doi.org/10.18632/oncotarget.26414
|
| 98-112 |
|
| Monitoring melanoma recurrence with circulating tumor DNA: a proof of concept from three case studies |
|
https://doi.org/10.18632/oncotarget.26451
|
| 113-122 |
|
| RASSF1C regulates miR33a and EMT marker gene expression in lung cancer cells |
|
https://doi.org/10.18632/oncotarget.26498
|
| 123-132 |
|
| Implication of calcium activated RasGRF2 in Annexin A6mediated breast tumor cell growth and motility |
|
https://doi.org/10.18632/oncotarget.26512
|
| 133-151 |
|
| Small molecule targeted NIR dye conjugate for imaging LHRH receptor positive cancers |
|
https://doi.org/10.18632/oncotarget.26520
|
| 152-160 |
|
| Lowdose eribulin reduces lung metastasis of osteosarcoma in vitro and in vivo |
|
https://doi.org/10.18632/oncotarget.26536
|
| 161-174 |
|
| Photoimmune therapy with liposomally formulated phospholipidconjugated indocyanine green induces specific antitumor responses with heat shock protein70 expression in a glioblastoma model |
|
https://doi.org/10.18632/oncotarget.26544
|
| 175-183 |
|
| Failures in preclinical and clinical trials of cMet inhibitors: evaluation of pathway activity as a promising selection criterion |
|
https://doi.org/10.18632/oncotarget.26546
|
| 184-197 |
|
| Molecular subtypes of triplenegative breast cancer in women of different race and ethnicity |
|
https://doi.org/10.18632/oncotarget.26559
|
| 198-208 |
|
| Immune checkpoint inhibitors in EGFRmutation positive TKItreated patients with advanced nonsmallcell lung cancer network metaanalysis |
|
https://doi.org/10.18632/oncotarget.26541
|
| 209-215 |
Reviews
|
| Circulating mediators of remote ischemic preconditioning: search for the missing link between nonlethal ischemia and cardioprotection |
|
https://doi.org/10.18632/oncotarget.26537
|
| 216-244 |
Case Reports
|
| ROS1GOPC/FIG: a novel gene fusion in hepatic angiosarcoma |
|
https://doi.org/10.18632/oncotarget.26521
|
| 245-251 |
Corrections
|
| Correction: Clinical characteristics and prognoses of patients treated surgically for metastatic lung tumors |
|
https://doi.org/10.18632/oncotarget.26575
|
| 252-252 |
|
| Correction: Incidence and risk of regorafenibinduced hepatotoxicity |
|
https://doi.org/10.18632/oncotarget.26576
|
| 253-253 |
|
| Correction: Incidence and risk of hematologic toxicities in cancer patients treated with regorafenib |
|
https://doi.org/10.18632/oncotarget.26577
|
| 254-254 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLCß
